ConductScience.org, home

Paper41520156

Actionable genomic landscape of biliary tract cancer in the Indian population.

Limaye S and 24 others. Oncologist, 2026. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Actionable genomic landscape of biliary tract cancer in the Indian population. Papers, record 41520156. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41520156

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Actionable genomic landscape of biliary tract cancer in the Indian population.
PubMed
Journal
Oncologist
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-08-13
PubMed

Authors25

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Limaye SSewantihttps://orcid.org/0009-0003-4989-9117
2Shreenivas AAditya
3Patil DDarshana
4Vyas SSoumil
5George IAIrene A
6Sambath JJanani
7Singh SShambhavi
8Madre CChetan
9Parab AAnjali
10Kataria PPritam
11Shah DDarshit
12Shah NNiyati
13Dawood SShaheenah
14Rohatgi NNitesh
15Deshpande RRuturaj
16Datta AAakriti
17Shamsi HAHumaid Al
18Gaya AAndrew
19Vaid AKAshok Kumar
20Kulkarni SShriniwas

Source PubMed

See all 25 authorsDownload CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
GenomicsMajor topic
Biliary Tract NeoplasmsMajor topic
Bile Duct NeoplasmsMajor topic
Humans
India
Male
Female
Mutation
Middle Aged
DNA Copy Number Variations
Aged
Retrospective Studies

Source PubMed

Download CSV of topics

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134730772Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma.JAMA Surg2022https://conductscience.org/library/papers/34730772PubMed
232416072Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol2020https://conductscience.org/library/papers/32416072PubMed
331015767Biliary tract cancers: current knowledge, clinical candidates and future challenges.Cancer Manag Res2019https://conductscience.org/library/papers/31015767PubMed
437386793Contribution of PGAP3 co-amplified and co-overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer.J Cell Mol Med2023https://conductscience.org/library/papers/37386793PubMed
538319896Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.NEJM Evid2022https://conductscience.org/library/papers/38319896PubMed
634554208Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.JAMA Oncol2021https://conductscience.org/library/papers/34554208PubMed
737444422Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies.Cancers (Basel)2023https://conductscience.org/library/papers/37444422PubMed
837709624Epidemiology of cholangiocarcinoma.Eur J Surg Oncol2025https://conductscience.org/library/papers/37709624PubMed
933744718STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications.Eur J Cancer2021https://conductscience.org/library/papers/33744718PubMed
1038626513Unresectable biliary tract cancer: Current and future systemic therapy.Eur J Cancer2024https://conductscience.org/library/papers/38626513PubMed
1124508317Molecular characterization of gallbladder cancer using somatic mutation profiling.Hum Pathol2014https://conductscience.org/library/papers/24508317PubMed
1235155243Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer.Front Oncol2022https://conductscience.org/library/papers/35155243PubMed
1340148974Epidemiology of gall bladder cancer and its prevalence worldwide: a meta-analysis.Orphanet J Rare Dis2025https://conductscience.org/library/papers/40148974PubMed
1435814257LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC.Front Pharmacol2022https://conductscience.org/library/papers/35814257PubMed
1532373065Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism.Front Endocrinol (Lausanne)2020https://conductscience.org/library/papers/32373065PubMed
1628008299KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers.Jpn Clin Med2016https://conductscience.org/library/papers/28008299PubMed
1737017301FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice.Pathologica2023https://conductscience.org/library/papers/37017301PubMed
1836372281Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Ann Oncol2023https://conductscience.org/library/papers/36372281PubMed
1935317947Meta-analysis on prognostic value of KRAS mutation in resected mass-forming cholangiocarcinoma.Eur J Surg Oncol2022https://conductscience.org/library/papers/35317947PubMed
2035871236Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.Br J Cancer2022https://conductscience.org/library/papers/35871236PubMed

See all 34 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42528623mTOR signaling in cholangiocarcinoma: mechanistic insights and therapeutic opportunities.Front Pharmacol2026https://conductscience.org/library/papers/42528623PubMed
42033611Genomic landscape and clinicopathological predictors of survival in gallbladder cancer.Clin Transl Oncol2026https://conductscience.org/library/papers/42033611PubMed
42010540Genomic landscape of cholangiocarcinoma in India: ethnic variants and implications for targeted therapy.BMC Cancer2026https://conductscience.org/library/papers/42010540PubMed

Download CSV of cited by

Genes14

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41520156

GET https://conductscience.org/api/papers/v1/41520156/authors?page=2